Abstract
In recent years, the world has been in a crisis of COVID-19, and there has been a decrease in research and studies in Al-Muthanna Governorate on this pandemic. Since these vaccines are new, many people are afraid of taking the vaccine, so this study decided to shed light on this field. The coronavirus that causes severe acute respiratory syndrome first comes into contact with mucosal surfaces (SARS-CoV-2). Most SARS-CoV-2 vaccinations produce targeted IgG responses but very moderate mucosal protection. Since the SARS-CoV-2 virus is transmitted through the respiratory tract and almost all COVID-19 vaccines are administered intramuscularly, it is challenging to successfully establish mucosal immunity to the antiviral through these means of administration. This study showed that (39) vaccinated individuals out of (74) patients were infected with COVID-19 and revealed positive results for qualitative IgM fluorescence immunoassay (FIA). Keywords: COVID-19 vaccines; Pfizer; Sinopharm; systemic vaccine; Mucosal Vaccine.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
